Inhibikase Therapeutics (IKT) Return on Equity (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Return on Equity for 6 consecutive years, with 0.67% as the latest value for Q3 2025.
- On a quarterly basis, Return on Equity rose 812.0% to 0.67% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.67%, a 812.0% increase, with the full-year FY2024 number at 0.54%, up 71.0% from a year prior.
- Return on Equity was 0.67% for Q3 2025 at Inhibikase Therapeutics, down from 0.53% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.24% in Q3 2021 to a low of 8.79% in Q3 2024.
- A 5-year average of 1.31% and a median of 0.67% in 2025 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: plummeted -763bps in 2024, then skyrocketed 812bps in 2025.
- Inhibikase Therapeutics' Return on Equity stood at 0.36% in 2021, then tumbled by -116bps to 0.78% in 2022, then tumbled by -97bps to 1.55% in 2023, then skyrocketed by 61bps to 0.61% in 2024, then decreased by -10bps to 0.67% in 2025.
- Per Business Quant, the three most recent readings for IKT's Return on Equity are 0.67% (Q3 2025), 0.53% (Q2 2025), and 0.43% (Q1 2025).